Cite
HARVARD Citation
van den Bent, M. et al. (2018). Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. Lancet oncology. 19 (9), pp. 1170-1179. [Online].